Adoptive T Cell Therapy Targeting CD1 and MR1.

Area of Science:

• Immunology
• Cellular Therapy
• Molecular Biology

Background:

• Adoptive T cell immunotherapy is effective for malignant and infectious diseases.
• Current therapies rely on T cells recognizing HLA molecules, limiting patient eligibility due to HLA allele diversity.
• This restricts the application of HLA-restricted T cell therapies.

Purpose of the Study:

• To review recent advancements in CD1 and MR1 molecule research.
• To explore the translational potential of T cells restricted by CD1 and MR1.
• To highlight alternative targets for T cell-based therapies.

Main Methods:

• Review of current literature on CD1 and MR1 molecules.
• Analysis of T cell receptor specificity for CD1- and MR1-restricted T cells.
• Evaluation of antigen presentation by CD1 (lipids) and MR1 (vitamin B metabolites).

Main Results:

• CD1 and MR1 are monomorphic, class I-like molecules, distinct from HLA.
• They present unique antigen classes: lipids (CD1) and vitamin B metabolites (MR1).
• T cells restricted by CD1 and MR1 offer novel therapeutic targets.

Conclusions:

• CD1 and MR1 molecules and their restricted T cells represent a promising frontier in immunotherapy.
• These pathways bypass HLA restrictions, potentially expanding patient eligibility.
• Further research into CD1/MR1-restricted T cells holds significant translational potential for treating various diseases.